Background. Acquired resistance to second-line drugs (SLDs) is a problem in treating patients with drug-resistant tuberculosis worldwide. The objectives of this study were to identify risk factors for acquired resistance (AR) to injectable SLDs (INJ SLDs) and fluoroquinolones in the US National tuberculosis Surveillance System, 1993System, -2008 Methods. We selected cases for which the initial and final drug susceptibility test (DST) results had been reported. We defined AR as resistance at the final DST but susceptibility to the same drug at the initial DST. We analyzed AR using 2-way frequency tables and multivariable logistic regression.
WHO at least 1 case of XDR tuberculosis [10] . Treatment outcomes among XDR tuberculosis patients are poor, and mortality rates are similar to the pre-antibiotic era. According to the results of a recent meta-analysis of 13 observational studies, treatment of XDR tuberculosis succeeded in only 43.7% of cases, and mortality was 20.8% [11] .
In the United States, 63 cases of XDR tuberculosis based on initial DST results have been reported in 1993-2011 (12, plus 6 cases in 2011, Centers for Disease Control and Prevention [CDC] , unpublished data). Little is known about the causes of acquired resistance to SLD during treatment, as most published reports to date have been descriptive [11] [12] [13] [14] [15] [16] [17] [18] [19] . As acquired resistance to second-line tuberculosis medications severely compromises treatment options for patients with MDR tuberculosis understanding the factors that lead to acquired resistance to SLD may help identify patients at risk and measures for prevention [3] .
To determine the frequency of and risk factors for acquired resistance to key second-line antituberculosis drugs, we analyzed data from the US National Tuberculosis Surveillance System (NTSS) for the years 1993-2008.
METHODS
We analyzed data from all culture-positive tuberculosis cases in the CDC's NTSS from all 50 states and the District of Columbia between January 1993 and December 2008 [20] . The NTSS includes sociodemographic and clinical information, as well as initial and final drug susceptibility test (DST) results. While DSTs for first-line drugs on the initial positive culture is routine in the United States, second-line DSTs and repeated DSTs are performed only when indicated. Final DST data and treatment outcomes are reported within 12 to 24 months after the end of treatment. All INJ SLDs (amikacin, kanamycin, capreomycin) and FQs (ofloxacin, ciprofloxacin) considered in this analysis were available for treatment in the United States from 1993 onward.
Case Definitions
We included in the analysis culture-positive cases with both initial and final DST results reported for second-line anti tuberculosis drugs, specifically, amikacin, kanamycin, capreomycin (injectable second-line drugs, INJ SLDs), ofloxacin and ciprofloxacin (fluoroquinolones, FQs). The initial DST is defined as the first available DST for a case; the final DST is defined as the last available DST for the same drug. Acquired resistance is defined as drug resistance at the final DST but susceptibility to the same drug at the initial DST.
In this nested case-control analysis, we defined a case as an individual who acquired resistance to at least 1 INJ SLD or 1 FQ during treatment. A control was defined as an individual who did not acquire resistance. We excluded cases that had resistance at the initial DST to INJ SLDs or FQs. All variables were defined according to their standard usage in the NTSS, which has been described in detail elsewhere [20] .
Statistical Analysis
We compared the distribution of demographic, social, and clinical characteristics among tuberculosis cases with vs without acquired SLD resistance, assessing differences in categorical variables with Pearson's chi square test. The specific demographic and social characteristics examined were gender, age, race/ethnicity, country of origin, illicit drug use, excess alcohol consumption, occupation, and any history of homelessness or imprisonment at the time of diagnosis. Clinical characteristics included a prior history of tuberculosis sputum-smear status at diagnosis, chest radiograph results (normal vs abnormal), radiographic abnormalities (cavitary vs non-cavitary disease), anatomic site of disease (ie, pulmonary or not pulmonary), HIV (human immunodeficiency virus) status, MDR tuberculosis, and specific drug regimens at the start of treatment.
We stratified the analysis of risk factors for acquired resistance by other covariates to assess any potential confounding and effect modification. Multivariable logistic regression was used to assess the independent associations between selected characteristics and acquired resistance. The criteria for including variables in the initial multivariable logistic regression model included a P value < .10 in the univariate analysis or a biologically plausible association with the outcome of interest. Odds ratios (OR) and 95% confidence intervals (CIs) were used to measure the magnitude and precision of the association of each factor with the outcome of interest. We used twosided tests of significance; P < .05 was considered statistically significant.
These data were collected and analyzed as part of routine public health surveillance, not as human subject research requiring institutional review board approval.
RESULTS
Among 222 897 culture-positive tuberculosis cases reported in the United States from 1993 to 2008, 31 733 (14.3%) had initial DST results for at least 1 SLD (Figure 1 ). Of these, 31 226 (98.4%) cases had initial DST results for at least 1 INJ SLD and 15 337 (48.3%) for at least 1 FQ; 14 830 (6.7%) had initial DST results that reported for both classes of SLDs. Of these, 14 770 cases also had initial DST results for isoniazid and rifampin. MDR tuberculosis was diagnosed in 1864 (12.6%) cases, and 56 (0.38%) had XDR tuberculosis at treatment initiation (baseline XDR).
Among 31 226 cases with initial DST results for INJ SLD, 2329 (7.5%) had final DST results for the same drug: 89% had both initial and final DST results for kanamycin, 16% for amikacin, and 70% for capreomycin. Of these, 43 cases had resistance to 1 INJ SLD at the initial DST but DST results for the other INJ SLDs were not reported; 12 cases were resistant to all INJ SLDs at the initial DST. Therefore, 55 cases could not have acquired resistance and were excluded from the analysis (Figure 1) . Kanamycin, amikacin, and capreomycin were included in the initial treatment regimen for 13 (0.6%), 35 (1.5%) and 58 (2.6%) cases, respectively. 
Risk Factors for Acquired Resistance to Injectable Second-Line Drugs
Of the 49 cases with acquired resistance to INJ SLDs, the majority (36/49, 73.5%) were aged 25 to 44 years; 27 (55.1%) were male, 21 (42.9%) were Hispanic, 27 (55.1%) were USborn, and 22 (44.9%) were unemployed (Table 1) . Twenty-two (45%) of these 49 cases were HIV-infected, 34 (69.4%) had MDR tuberculosis at the beginning of treatment, and 19 (38.8%) had an initial treatment regimen that included at least 1 SLD ( potential effect modifiers among sociodemographic and clinical characteristics. Multivariable logistic regression revealed that significant predictors of acquired resistance to INJ SLDs included age group 25-44 years (aOR, 2.7; 95% CI, 1.2-6.3), positive HIV status (aOR, 2.5; 95% CI, 1.3-4.7), MDR tuberculosis at initial DST (aOR, 5.5; 95% CI, 2.9-10.5), and initial treatment with any SLD (aOR, 2.4; 95% CI, 1.2-4.7).
Risk Factors for Acquired Resistance to Fluoroquinolones
Among 32 persons who acquired resistance to FQ, the majority were male (22/32, 68.8%), 15 were aged 25 to 44 years (46.9%), 13 (40.6%) were Hispanic, 17 (53.1%) were US-born, 19 (59.4%) were unemployed, 5 (15.6%) used illicit drugs, and 2 (6.3%) were homeless (Table 1) . Nine (28.1%) patients with acquired resistance to FQ were HIV-infected, 24 (75.0%) had MDR tuberculosis at the beginning of tuberculosis treatment, and 10 (31.3%) had an initial treatment regimen that included at least 1 SLD ( Table 2 ). The majority had pulmonary disease (25/ 32, 78.1%). Six (21.4%) were sputum-smear negative at the start of treatment and 4 (12.5%) had previous tuberculosis episodes. Univariate analysis showed that significant predictors of acquired resistance to FQ were MDR tuberculosis at the initial DST (OR, 6.5; 95% CI, 2.9-14.3) and having at least 1 SLD included in the initial treatment regimen (OR, 2.3; 95% CI, 1.1-4.9) ( Table 4 ). Multivariable analysis revealed that MDR tuberculosis at the initial DST (aOR, 6.5; 95% CI, 2.9-14.6) was the only statistically significant risk factor for acquired resistance to FQs.
DISCUSSION
This study provides the first comprehensive assessment of predictors of acquired resistance to 2 key classes of second-line antituberculosis drugs-fluoroquinolones and second-line injectable agents. From 1993 to 2008, among culture-positive tuberculosis cases with both initial and final DST results, 49 (2.2%) acquired resistance to INJ SLDs and 32 (2.8%) acquired resistance to FQs. Five baseline MDR tuberculosis cases acquired resistance to both INJ SLDs and FQs, and thus developed XDR tuberculosis. The number of cases with acquired drug resistance declined after 1993. The decrease in the frequency of AR beginning in 1993 may be attributed to the public health response to the tuberculosis epidemic, including greatly improved tuberculosis control activities and an increased proportion of patients treated under directly observed therapy (DOT) in the United States from that time. However, acquisition of resistance to SLD in the United States continues to occur.
MDR tuberculosis was an independent predictor of AR to INJ SLDs and FQs, and it was the only predictor for acquired resistance to FQs. Acquired resistance to INJ SLDs was also independently associated with HIV status and having any SLD in the initial treatment regimen. The age group of 25-44 years was the only demographic predictor for acquisition of resistance to INJ SLDs, increasing the odds 2.7-fold. In this age group, cases that acquired resistance include a substantially higher proportion of HIV-infected cases and illicit drug users compared with controls. No statistically significant association was identified between previous tuberculosis treatment and the acquisition of resistance to either group of SLDs. The risk factors for acquired resistance to the injectable drugs and the FQs could be different because INJ SLDs have been available in the United States since the 1950s, while FQs have been used for tuberculosis treatment only since the 1990s. Therefore, the sample size for acquired resistance to FQs is smaller than for INJ SLDs, especially in the 25-44 age group and among those who were HIV-positive.
Several groups have reported the development of FQ-resistant tuberculosis and XDR tuberculosis during treatment [6] [7] [8] [9] [10] [11] [12] [13] [14] , but not predictors for acquisition of resistance. There are very few publications on the acquisition of SLD resistance, likely due to a lack of capacity for laboratory testing [21, 22] . Treatment with SLDs was associated with XDR tuberculosis in South Korea and also in Tugela Ferry, South Africa [21, 22] . Having MDR tuberculosis at the start of treatment appears to be the strongest consistent factor for acquired resistance to SLDs.
Our study has several limitations. Drug susceptibility testing of M. tuberculosis to first-line drugs is performed and reported routinely in the United States, but the testing of SLDs and repeat testing is performed on an individual basis according to physician requests. Most cases in the NTSS had no reported DST results for SLDs and no repeat DSTs after the initial testing. Therefore, our results did not reflect SLD resistance among all reported tuberculosis cases, but only among those with reported results. In addition, among all cases with initial DST results that were reported, 10.3% (3207/31 226) in the INJ SLD group and 9.9% (1516/15 337) in the FQ group died, while about 3% (979/31 226 in the INJ SLD group and 501/ 15 337 in the FQ group) were lost to follow-up without final DST results. Thus, this study underestimates the real number of cases with acquired SLD resistance in the United States, but it is based on the most complete national data currently available. Also, as genotyping of both the initial and final isolates was not available, we could not ensure that the same strain was tested. Therefore, we could not exclude infection with mixed strains, re-infection, or laboratory errors. However, the risk of re-infection during tuberculosis treatment in the United States is low [23, 24] . The US National Tuberculosis Genotyping Service database may help address these issues in the future [25] . Finally, only the initial treatment regimen is reported in the NTSS, and important changes to tuberculosis therapy could be made during treatment. Accordingly, we did not have detailed information regarding tuberculosis treatment for this analysis. The CDC has recently established an MDR/ XDR tuberculosis registry that collects information on treatment regimens with the aim to further investigate this issue.
In conclusion, our study demonstrated that in spite of declining trends in SLD resistance, the problem of acquired SLD resistance, while rare, still persists in the United States. The proportion of acquired resistance was larger among MDR tuberculosis patients, patients with positive HIV status, and those who received SLDs in the initial treatment regimen. Resistance to second-line tuberculosis medication severely compromises the treatment regimen options for tuberculosis patients, and therefore, the identification of patients at risk and prevention of further resistance is important. Patients in these subgroups should be prioritized for fast-track DSTs and rapid molecular drug resistance tests, and strictly follow supervised treatment based on the drug susceptibility test results. Earlier identification of patients at risk for developing XDR tuberculosis enables more diligent infection control measures, which are critical for preventing transmission of the disease.
Notes

